A Schisandra compound slowed pancreatic tumours by breaking their mitochondria — in cancer cells and mouse xenografts

Edited by Samael A. Tejada, Founder & Editor-in-Chief

Most mitochondrial medicine tries to protect the organelle. Cancer research sometimes aims the other way: a tumour's mitochondria, broken on purpose, can be the lever that kills the cell. This study tests that lever in the hardest of cancers.

How was Schisandrin B studied?

The team began computationally: network pharmacology identified EGFR, CASP3, BCL2 and HSP90 as key candidate targets of Sch B in PDAC, and molecular docking plus molecular-dynamics simulation explored how the compound might interact with those proteins. They then tested the predictions experimentally, in cultured pancreatic cancer cells and in a PANC-1 xenograft model in mice. That sequence — computation nominating, experiments testing — is the standard modern pipeline for natural-product pharmacology, and it matters that the animal arm was included rather than stopping at docking scores.

What happened to the cancer cells' mitochondria?

After 48 hours of Sch B treatment, PDAC cell viability fell. The mechanistic signature centred on mitochondria: mitochondrial membrane potential dropped, mitochondrial and cytosolic calcium rose, and reactive oxygen species production increased, alongside activation of apoptotic signalling — the cell-death program mitochondrial injury feeds into. EGFR/AKT/mTOR signalling, a growth pathway pancreatic cancers commonly exploit, was suppressed in parallel. When Sch B was combined with gemcitabine, the chemotherapy backbone for PDAC, the apoptotic and oxidative-stress effects were enhanced, suggesting — in this model — a combination worth further study.

What happened in the animal model — and what are the limits?

In the PANC-1 xenograft model, Sch B significantly reduced tumour growth, and tumour tissue showed decreased protein expression of EGFR, AKT, mTOR and HSP90, consistent with the cell experiments. The limits are the usual preclinical ones, and they are substantial: a single cell line grown as a xenograft in immunocompromised mice does not reproduce human pancreatic cancer's stroma, immune environment or chemoresistance; docking results are predictions, not measurements of binding in patients; and there are no human pharmacokinetic, safety or efficacy data for Sch B in pancreatic cancer. Schisandra supplements sold to consumers are not this experiment and are not a cancer treatment.

Where the evidence stands

• Established: PDAC is highly lethal with limited treatment options and prominent chemoresistance; mitochondrial membrane-potential loss, calcium overload and ROS elevation are established drivers of apoptosis in cancer-cell models; gemcitabine is a standard PDAC chemotherapy.
• Preliminary: Sch B's anti-PDAC activity: one preclinical study (2026) combining network pharmacology and docking with cell experiments and a single PANC-1 xenograft model. No independent replication.
• Absent: Human evidence — no clinical trial, dosing, pharmacokinetic or safety data for Schisandrin B in pancreatic cancer.